POPULARITY
One in four Americans is enrolled in Medicaid, yet the system designed to support them is constantly at risk—underfunded, politically vulnerable, and often overlooked.Dr. Alastair Bell, President and CEO of Boston Medical Center Health System, shares how his organization is reimagining what it means to care for underserved populations, while managing nearly 40% of Massachusetts' Medicaid enrollees. In this conversation, we explore the financial realities of running an “essential” hospital system, the opportunities and pitfalls of Medicaid ACOs, and why AI might deepen inequity if essential providers are left behind.We cover:
Nearly 9 in 10 pharmacists are at a high risk of burnout, but how do affected pharmacists find a path forward? In this episode, we sit down with Devan Conley, Pharmacist at TrueCare Pharmacy in Concord, NC, to find out firsthand. Devin discusses his journey with burnout—which crept up during COVID and kept on for years, culminating in a struggle with prescription misuse. But, more importantly, Devan shares how he recovered, and how that recovery reshaped the way that he approaches life and pharmacy alike. Today, Devan is a pharmacist at a 340B pharmacy inside a federally qualified health center, launching behavioral health and harm reduction programs so that anyone dealing with similar struggles can find support. Devan's message is clear: Burnout doesn't have to be the end of your story but the beginning of a new one. 00:00 - Introduction to Devan Conley & TrueCare Pharmacy 02:00 - Burnout During COVID and Its Lasting Impact 08:40 - Path to Recovery and Regaining His Pharmacy License 18:50 - Opening a 340B Pharmacy in a Behavioral Health Setting 26:20 - Expanding Services with Long-Acting Injectables & Women's Health 33:10 - Harm Reduction Initiatives and Narcan Program 47:50 - Lessons in Leadership, Resilience, and Community Impact 52:20 - Closing Thoughts & How to Connect with Devan Hosted By: Mark Bivins | Chief Growth Officer, RedSail Technologies Guest: Devan Conley | Pharmacist, TrueCare Pharmacy Devan's LinkedIn: https://www.linkedin.com/in/devan-conley-pharmd-msph-8732b87a/
Dr. Anthony DiGiorgio, a neurosurgeon at UCSF with a strong interest in healthcare policy, joins the show to unpack the complex and often misunderstood world of Medicaid. In a wide-ranging and nuanced discussion, he explores who qualifies for coverage, why most Medicaid spending goes to groups people don't typically expect, and whether the system should be expanded or fundamentally reformed. Dr. DiGiorgio outlines his support for a robust safety net, emphasizing targeted subsidies over a government-run program, and offers his take on the proposed “Big Beautiful Bill” currently in Congress. Along the way, the conversation touches on broader healthcare issues including the 340B drug discount program, the Affordable Care Act, and the role of the free market in ensuring access to care. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
In this episode, Greg and Rob share initial thoughts on 340B Rebate Model Guidance released by HRSA on July 31st. They also catch up on some of the hot topics that were generating conversations at the recent 340B Coalition Summer Conference Meeting.
Subscribe to UnitedHealthcare's Community & State newsletter.Health Affairs' Jeff Byers welcomes Senior Editor Leslie Erdelack back to the pod to discuss the proposed rule change to the Medicare Physician Fee Schedule for 2026, which includes payment conversion factors for doctors, alternative payment models, add-on codes for Advanced Primary Care Management services, a new mandatory value-based payment model, and more.Order the August 2025 issue of Health Affairs.Join us for a live taping of A Health Podyssey on Tuesday August 12 where Rob Lott will discuss recent findings about changes in clinician's participation across Medicare value-based payment models with Kenton Johnston.Upcoming Events include:8/20: 340B w/ Sayeh Nikpay (INSIDER EXCLUSIVE)8/26: Provider Prices in the Commercial Sector: Independent Dispute Resolution (FREE TO ALL)9/23: Prior Authorization: Current State and Potential Reform (INSIDER EXCLUSIVE)View all Upcoming Events.Become an Insider today to get access to exclusive events like the ones highlighted above.Related Articles:PRESS RELEASE: Calendar Year (CY) 2026 Medicare Physician Fee Schedule (PFS) Proposed Rule (CMS-1832-P)CMS proposes rule aligning Medicare physician payment with ‘Big Beautiful Bill,' MACRA (Healthcare Dive)CMS proposes 3.6% pay bump for docs, takes aim at chronic conditions in physician fee schedule (Fierce Healthcare)Physicians will see Medicare payments rise in 2026 (AMA)Medicare proposes ‘efficiency' pay cuts that would hit highly paid specialists the most (STAT News) Subscribe to UnitedHealthcare's Community & State newsletter.
This Day in Legal History: Gulf of Tonkin ResolutionOn August 7, 1964, the U.S. Congress passed the Gulf of Tonkin Resolution, dramatically reshaping the legal landscape of American military engagement. Prompted by reports—later disputed—of North Vietnamese attacks on the USS Maddox in the Gulf of Tonkin, the resolution granted President Lyndon B. Johnson broad authority to use military force in Southeast Asia without a formal declaration of war. It passed nearly unanimously, with only two dissenting votes in the Senate, reflecting the tense Cold War atmosphere and congressional trust in the executive branch.Legally, the resolution functioned as an open-ended authorization for the president to escalate military operations in Vietnam. Within months, it led to the deployment of hundreds of thousands of U.S. troops. Critics would later argue that it allowed the executive to bypass Congress's constitutional war-making powers, effectively green-lighting a years-long conflict based on contested facts.As the war dragged on and public opinion turned, the resolution became a focal point for debates over separation of powers, congressional oversight, and executive overreach. In 1971, amid growing backlash, Congress repealed the resolution, but its legacy endured. It served as a legal and historical precedent for future authorizations of force, including those passed after 9/11.A federal appeals court has upheld the SEC's long-standing “gag rule,” which prevents defendants who settle civil enforcement cases from publicly denying the agency's allegations. The 9th Circuit Court of Appeals ruled 3-0 that the rule is not unconstitutional on its face but left room for future challenges depending on how it's applied. The policy, in place since 1972, requires settling parties to at least refrain from admitting or denying wrongdoing. The court emphasized that defendants remain free to reject settlements if they wish to speak out.Twelve petitioners, including former Xerox CFO Barry Romeril and the New Civil Liberties Alliance (NCLA), challenged the SEC's January 2024 decision not to revise the rule. Romeril had previously brought a similar challenge to the Supreme Court with support from Elon Musk, but the Court declined to hear it. Writing for the panel, Judge Daniel Bress noted that removing the gag could reduce the SEC's ability to settle cases efficiently and that speech restrictions are voluntary components of settlement agreements.The NCLA criticized the decision, arguing it effectively sanctions government-imposed silence and announced plans to pursue further appeals. SEC Commissioner Hester Peirce also dissented from the agency's refusal to revisit the rule, arguing that it hinders public accountability by suppressing potential criticism. The SEC declined to comment on the ruling, which came in the case Powell et al v. SEC.US appeals court upholds SEC 'gag rule' over free speech objections | ReutersThe Stanford Daily, Stanford University's student newspaper, has filed a lawsuit against the Trump administration, accusing it of violating the free speech rights of foreign students. The suit, filed in federal court in California, alleges that threats of arrest, detention, or deportation have created a climate of fear among international students, discouraging them from writing about sensitive political issues—particularly the Israeli-Palestinian conflict. Two unnamed students joined the paper in the lawsuit, which names Secretary of State Marco Rubio and Secretary of Homeland Security Kristi Noem as defendants.According to the plaintiffs, the administration has labeled pro-Palestinian viewpoints as antisemitic or extremist and attempted to deport students expressing such views, framing them as threats to U.S. foreign policy. In some instances, students have been detained without charges, though judges have later ordered their release. The lawsuit contends that these actions have led to widespread self-censorship among international students, chilling constitutionally protected speech in areas such as protests, slogans, and commentary on U.S. and Israeli policy.The Stanford Daily is seeking a court ruling affirming that the First Amendment protects non-citizens from government retaliation based on their speech. The university clarified it is not involved in the suit, as the newspaper operates independently. Attorney Conor Fitzpatrick, representing the paper, called the government's actions antithetical to American values of free expression.Stanford student newspaper sues Trump administration for alleged free speech violations | ReutersA U.S. appeals court has reinstated a lawsuit accusing major drugmakers Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to limit drug discounts provided under the federal 340B program. The 2nd Circuit Court of Appeals reversed a lower court's dismissal, allowing two health clinics—Mosaic Health and Central Virginia Health Services—to proceed with their proposed class action. These clinics claim the companies colluded in 2020 to restrict discounts on diabetes medications, harming safety-net providers and the low-income patients they serve.The court found that because the four companies control much of the diabetes drug market, coordination to limit discounts could be feasible. Judge Myrna Pérez, writing for the panel, noted the allegations were plausible enough to move forward. The drugmakers have denied wrongdoing and argue their policies were developed independently to address alleged fraud in the 340B program. Sanofi and Novo Nordisk said they are reviewing the decision, while Lilly criticized the ruling and defended its practices as legal.The clinics say the drugmakers earned billions in extra profits through these policies, which allegedly undercut essential savings for providers. The case underscores the broader tension between pharmaceutical companies and healthcare providers over the administration of the 340B program, which requires drugmakers to offer discounts in exchange for access to federal healthcare funds.US appeals court reinstates drug-price conspiracy lawsuit against Sanofi, rival pharma companies | ReutersPepsiCo is facing a proposed class action lawsuit alleging it engaged in illegal price discrimination by giving more favorable pricing and discount terms to large retailers like Walmart while denying the same deals to smaller businesses. Filed in federal court in Manhattan by an Italian restaurant operator, the lawsuit claims this practice violates the Robinson-Patman Act, a rarely enforced 1936 antitrust law meant to prevent discriminatory pricing that harms competition.The suit accuses Pepsi of providing payments and allowances to Walmart that were not extended to other retailers, placing smaller businesses at a competitive disadvantage. Although Walmart is named in the allegations, it is not a defendant in the case. The plaintiff argues that Pepsi's pricing tactics unfairly burden other merchants who must pay more for the same products.This legal action echoes a previous Federal Trade Commission (FTC) lawsuit filed against Pepsi in January under the Biden administration. However, the second Trump administration dropped the case in May, with Trump-appointed FTC Chair Andrew Ferguson criticizing it as a politically motivated effort launched too late in the prior administration's term. The FTC has not commented on the new private lawsuit.The class action seeks unspecified damages on behalf of thousands of Pepsi purchasers nationwide. Neither Pepsi nor Walmart has publicly responded to the allegations.Pepsi accused of price discrimination in new merchant class action | Reuters This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.minimumcomp.com/subscribe
This episode features Paige Twenter, Assistant Editor at Becker's Hospital Review, as she discusses key healthcare policy developments including restrictions on gender-affirming care, federal pressure on pharmaceutical companies to lower U.S. drug prices, and major changes to the 340B drug pricing program.
Si, aujourd'hui, je parle en faisant bien attention de ne pas mettre un mot plus haut que l'autre, de maintenir ma parole dans des bornes qui la condamne à ne trouver aucun souffle expressif, c'est comme une manière en creux de venir faire la preuve que l'espace de parole qui est ici mis à ma disposition … Continuer la lecture de « Metaclassique #340b – Surjouer »
Patients with behavioral health and substance use disorders often struggle with accessing and staying on the daily oral medications they need to keep their disorders controlled. That's why SSM Health uses some of its 340B savings to run long-acting injectable (LAI) clinics in the St. Louis area to help these patients achieve better health. We speak with SSM Health Vice President of Pharmacy Financial Operations Michelle Schmitt to learn how much of a role 340B plays in that patient care mission.LAI clinics offer comprehensive servicesSSM Health's three LAI clinics offer injections for patients with conditions such as bipolar disorder, schizophrenia, and alcohol and opioid use disorders that might last as long as three to six months. Clinic visits also give the patients access to a full team of pharmacists, psychiatrists, nurses, therapists, and others to help them navigate treatment and stay healthy.340B funds are key to patient accessBecause behavioral health is often a subsidized service, 340B savings are crucial to the operations of the clinics. They also enable SSM Health to offer financial assistance to patients living up to 400% of the poverty level so they can afford the treatments they need to stay on the road to recovery.Cuts to 340B would be detrimental to patientsSchmitt says losing access to 340B pricing could mean a 60-70% price increase in the cost of LAI drugs, which would threaten the viability of the clinics and the financial assistance that many patients rely on to access their treatments. She says these clinics are a great example of how 340B is about much more than just price discounts; it provides resources for health systems to meet unique community health needs and serve patients where they are.ResourcesFederal Legislation Would Ban Harmful Drug Company Restrictions on 340B
Federal legislation has been introduced that is intended to help the beleaguered 340B Health organization via an effort to ban pharmaceutical companies from restricting access to the drug pricing discount program of the same name, through community and specialty contract pharmacies.Reporting this lead story as well as other updates from Congress and the Trump Administration during the next live edition of Monitor Mondays will be Maureen Testoni, CEO for 340B Health and a frequent guest on the long-running broadcast. Testoni represents more than 1,600 hospitals and health systems participating in the 340B drug pricing program.The weekly broadcast will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Cate Brantley, senior healthcare government affairs analyst for Zelis, will report on the news happening at the intersection of healthcare and congressional action.
In this episode, Steven Newmark, Chief of Policy at GHLF, is joined by Clayton Ruley, Director of Strategic Initiatives, Mission Advancement & Impact at the Community Liver Alliance. Clayton shares his decades-long journey from frontline harm reduction work to shaping national health policy. Together, they discuss the need for compassion in healthcare, the importance of patient-centered policymaking, and the urgent challenges facing programs like 340B and Medicaid. Clayton also highlights how community-level work and federal health policies intersect — and why transparency and access matter now more than ever. Among the highlights in this episode: 01:04: Clayton describes his background and early career, influenced by a family of social workers and his work in harm reduction clinics 04:04: Clayton explains what policymakers often miss: the need for options, compassion, and respect in patient care, especially for people facing stigma or systemic barriers 07:05: Clayton outlines the mission of the Community Liver Alliance and his evolving role in expanding national and global impact 09:56: Clayton discusses the top policy priorities for the Community Liver Alliance, including improving transparency and accountability in the 340B program 14:30: Clayton gives real-life examples of how 340B funding can transform communities through housing, outreach, and treatment access 15:55: Clayton and Steven discuss the harms of non-medical switching and the need to protect patient stability in treatment 16:52: They highlight concerns about potential Medicaid and Medicare cuts and the downstream impact on underserved communities 17:22: Steven reminds listeners of the delayed consequences of the Build Back Better bill, with millions projected to lose Medicaid access by 2027 18:54: Clayton warns that rising premiums could force patients to forgo insurance entirely — a dangerous outcome for people with chronic diseases To learn more about the Community Liver Alliance or support their advocacy efforts, visit: https://communityliveralliance.org/ Contact Our Host Steven Newmark, Chief of Policy at GHLF: snewmark@ghlf.org A podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF. We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.org Listen to all episodes of The Health Advocates on our website (https://ghlf.org/the-health-advocates) or on your favorite podcast channel.See omnystudio.com/listener for privacy information.
In this episode of The Hydrogen Podcast, host Paul Rodden unpacks two major stories that reveal the tension—and opportunity—in hydrogen's global rollout:
This week's episode is a short one but a good one. Rob is out on vacation, so Greg is joined by SpendMend colleague Sabrina Allen to discuss the recent policy changes impacting FQHCs related to a Trump Administration executive order from earlier this year that address insulin and injectable epinephrine 340B pricing provisions. SpendMend is at Booth #413 this week at the 340B Coalition Summer Conference in National Harbor, MD. Come meet our team, eat some chocolate and discuss what's happening in the 340B world. Webinar Alert! Join us for a webinar on 340B Patient Definition on Thursday July 24 at 2PM ET. Register here: https://attendee.gotowebinar.com/register/1724500873792685151?source=340B+Unscripted
About three years after being signed into law, one provision of the Inflation Reduction Act (IRA) that is of particular importance to 340B hospitals is about to take effect: Medicare price caps. Jan. 1, 2026, marks the date that the first 10 Medicare drugs will be subject to a maximum fair price (MFP). Meetali Desai, director of pharmacy business services at UMass Memorial Medical Center, joins us to explain how this will affect 340B hospitals and health centers such as hers.The Good and Bad News for Covered EntitiesThe good news, Desai says, is that there is potential for the 340B ceiling prices to go down for certain medications. This is because the MFP will become the new “best” price in the formula for calculating 340B prices. However, because the law will cap reimbursement rates to MFP when Medicare patients receive those drugs, 340B hospitals will see their 340B savings amounts go down for those dispenses.Updated Calculator Can Help Hospitals Gauge Potential Impact340B Health recently updated its calculator for hospitals to use to estimate the effects of MFP pricing based on the newest data. This new calculator allows users to project what the potential impact from the IRA could be on a hospital, including if drugmakers decide to lower their list prices significantly to avoid IRA inflation penalties. This drop in prices of Medicare drugs could result in 340B hospitals seeing higher ceiling prices and reduced savings.Reduced Savings Could Impact Patient CareDesai says Medicare price caps, combined with other financial pressures on hospitals, could mean some rough times ahead for hospitals that care for a large proportion of low-income patients. She encourages 340B teams to share their results from the IRA calculator with their senior leadership and with 340B Health as the hospital community prepares for the impact of these caps.ResourcesUse Our IRA Calculator and Share How Your 340B Savings Will ChangeRead Our Analysis: Second Federal Court Affirms HRSA's Authority Over 340B Rebates
In this special policy-focused episode of The ASHHRA Podcast, co-hosts Bo Brabo and Luke Carignan welcome back three powerhouse experts to help us navigate the urgent challenges facing hospital HR leaders today:
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medical societies, including the American Academy of Pediatrics, have filed a lawsuit against RFK Jr. over changes to COVID-19 vaccine policies. They argue that his directive to remove COVID-19 from vaccination guidelines for healthy pregnant women and children puts them at risk of serious illness. Concentra has acquired struggling biotech company Cargo Therapeutics in a $200 million buyout. President Trump's tax law has restored orphan drug exemptions, cut Medicaid funding, and threatened the 340B program, while giving pharmacy benefit managers a pass. The ALS community has petitioned the FDA to reconsider Brainstorm's cell therapy Nurown, citing recent survival data. Drug developers are exploring new digitization strategies to optimize processes and embrace technology in drug development. Overall, the text discusses legal action against RFK Jr. over vaccine policy changes, recent acquisitions in the biotech industry, implications of Trump's tax law on healthcare programs, petitions regarding ALS therapies, digitization strategies in drug development.
Howie and Harlan discuss the alarming healthcare cuts proposed in the budget bill currently moving through Congress, recent breakthroughs in HIV prevention and diabetes treatment, and the stark contrast between scientific progress and the deep structural flaws in the U.S. healthcare system. Links: The Budget Bill H.R.1—119th Congress (2025-2026) “A List of Nearly Everything in the Senate G.O.P. Bill, and How Much It Would Cost or Save” “Senate passes Trump's tax-cut bill that would slash Medicaid spending” “5 ways Trump's tax bill will limit health care access” “Murkowski Casts Decisive Vote for G.O.P. Policy Bill, Making an ‘Agonizing' Choice” “Mapping Hospital Employment By State” “Health Care Just Became the U.S.'s Largest Employer” The Budget Bill and Universities Yale Office of the Provost: “Actions in anticipation of federal legislation” “Yale pauses hiring, tightens budget in anticipation of endowment tax hike” “Yale Is Rushing to Sell Billions in Private Equity Investments” “Trump Has Targeted These Universities. Why?” “Republican Plan to Tax Elite Colleges Could Hit in Unexpected Places” “The NIH's drastic cut to indirect cost rates is a critical threat to U.S. research infrastructure” The 340B Drug Program Congressional Research Service: Overview of the 340B Drug Discount Program “J&J suffers a loss over 340B drug discount program” “ Beyond the Sloganeering—A Data-Driven Analysis of Recent 340B Growth” American Hospital Association: Fact Sheet: The 340B Drug Pricing Program PhRMA: The 340B Hospital Markup Program A Stem Cell Treatment for Diabetes “Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin” “Kennedy Says ‘Charlatans' Are No Reason to Block Unproven Stem Cell Treatments” Mayo Clinic: “Stem cells: What they are and what they do” Cleveland Clinic: Diabetes “Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes” Medicare Advantage and the VA “Insurers Collected Billions From Medicare for Veterans Who Cost Them Almost Nothing” “Lawmakers Seek to Close VA Loophole That Funnels Billions to Private Medicare Insurers” “Medicare Advantage Plans With High Numbers Of Veterans: Enrollment, Utilization, And Potential Wasteful Spending” A New HIV Drug HIV.gov: A Timeline of HIV and AIDS “HIV protection with just two shots a year: FDA approves Gilead drug” “Shuttering of USAID Will Lead to Millions of Deaths Around the World: Studies” “Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis” Kennedy v. Braidwood Health & Veritas Episode 84: Abbe Gluck: The Legal Determinants of Health Supreme Court opinion: KENNEDY, SECRETARY OF HEALTH AND HUMAN SERVICES, ET AL. v. BRAIDWOOD MANAGEMENT, INC., ET AL. “Kennedy v. Braidwood: The Supreme Court Upheld ACA Preventive Services but That's Not the End of the Story” “Supreme Court Upholds Preventive Services Requirement Under ACA” The Big Picture for U.S. Healthcare “The Perfect Storm has Hit U.S. Healthcare” “National Health Expenditure Projections, 2024–33: Despite Insurance Coverage Declines, Health To Grow As Share Of GDP” Exercise and Cancer “Structured Exercise after Adjuvant Chemotherapy for Colon Cancer” Learn more about the MBA for Executives program at Yale SOM. Email Howie and Harlan comments or questions.
Welcome back to the Alt Goes Mainstream podcast.Today's conversation dives into the current state of private markets through the lens of one of the leading GP stakes firms in the industry.We sat down with Partner and Global Co-Head of the Petershill Group at Goldman Sachs Robert Hamilton Kelly. Petershill takes minority equity stakes in established and newly-established alternative asset managers. Across its different investment vehicles, Petershill participates in the fee income from over 200 underlying funds from alternative asset management firms that are diversified across asset class, investment strategy, and investment lifecycle.Petershill's Partner firms have well in excess of $340B in aggregate AUM and they've partnered with a number of the top firms and some of the industry's most recognizable names in the middle market and upper end of the market, including Clearlake, Francisco Partners, Permira, Accel-KKR, General Catalyst, Kayne Anderson Real Estate, Kennedy Lewis, and more.Rob and I had a fascinating conversation on GP stakes and the evolution of alternative asset management. We discussed:The what, why, and how of GP stakes.The benefits and drawbacks of GP stakes investing for GPs and LPs.What makes a great GP.The question of liquidity in GP stakes.Why Petershill has generally focused on middle-market alternative asset managers.How private markets will continue to evolve and the growing importance of the wealth channel in the evolution of asset management.Thanks Rob for coming on the show to share your wisdom and expertise in private markets and GP stakes. We hope you enjoy.A word from AGM podcast sponsor, Ultimus Fund SolutionsThis episode of Alt Goes Mainstream is brought to you by Ultimus Fund Solutions, a leading full-service fund administrator for asset managers in private and public markets. As private markets continue to move into the mainstream, the industry requires infrastructure solutions that help funds and investors keep pace. In an increasingly sophisticated financial marketplace, investment managers must navigate a growing array of challenges: elaborate fund structures, specialized strategies, evolving compliance requirements, a growing need for sophisticated reporting, and intensifying demands for transparency.To assist with these challenging opportunities, more and more fund sponsors and asset managers are turning to Ultimus, a leading service provider that blends high tech and high touch in unique and customized fund administration and middle office solutions for a diverse and growing universe of over 450 clients and 1,800 funds, representing $500 billion assets under administration, all handled by a team of over 1,000 professionals. Ultimus offers a wide range of capabilities across registered funds, private funds and public plans, as well as outsourced middle office services. Delivering operational excellence, Ultimus helps firms manage the ever-changing regulatory environment while meeting the needs of their institutional and retail investors. Ultimus provides comprehensive operational support and fund governance services to help managers successfully launch retail alternative products.Visit www.ultimusfundsolutions.com to learn more about Ultimus' technology enhanced services and solutions or contact Ultimus Executive Vice President of Business Development Gary Harris on email at gharris@ultimusfundsolutions.com.We thank Ultimus for their support of alts going mainstream.Show Notes00:00 Introduction and Sponsor Message01:18 Podcast Opening and Theme02:06 Guest Introduction: Robert Hamilton Kelly03:32 Rob's Boat Racing Experience03:45 Parallels Between Boat Racing and Private Markets04:57 Current State of Private Markets05:14 Impact of Policy Changes on Private Markets06:53 Growth of the Private Markets Industry07:09 Early Days of Petershill07:26 Goldman's Role in Alternative Asset Management09:26 Valuing GP Stakes and Alternative Asset Managers10:01 Insights on Alternative Asset Managers12:36 Valuing GP Stakes13:22 Data-Driven Investment Strategies15:34 Management Fees and Performance Fees16:28 Growth and Evolution of Firms23:16 Strategic Imperatives for Growth26:15 Managerial Skills and Industry Dynamics30:55 Commercialization in Platform Management31:07 Challenges and Opportunities in Capital Raising31:53 Industry Consolidation Predictions32:29 Growth and Consolidation in Private Markets33:31 The Role of Mid-Market Firms34:15 GP Stakes and Wealth Channel Access36:12 Goldman's Unique Platform and Services37:57 The Importance of Strategic Advice39:39 Common Challenges for GPs40:33 Evolving LP and GP Stakes Dynamics40:44 Why LPs Invest in GP Stakes42:00 Income Generation and Capital Growth42:49 Diversification in GP Stakes43:05 Private Markets Exposure44:01 Entry Points into Private Markets45:07 Long-Term Exposure and Portfolio Construction47:00 Investing in Private Credit48:10 Evaluating GP Stakes Investments49:38 Data and Performance in GP Stakes52:04 Growth Path of Private Markets52:23 Valuing Alternative Asset Managers55:41 Liquidity in GP Stakes57:09 Structural Changes in GP Stakes57:35 The Evolution of Private Markets58:11 Future of Venture and Growth Sectors58:56 Private Credit Products and Market Share59:29 Maturation of Private Markets59:52 Conclusion and Final Thoughts
In this episode, Greg and Rob welcome back Ted Slafsky to recap what the first six months of 2025 have brought to the 340B landscape. They'll talk about where we are at with 340B rebate model action, discuss how federal agency reorganization efforts could impact 340B regulatory oversight, recap state legislative wins for 340B providers and debate how Congress may address the call for 340B Program reform later in the year. Come catch us at Booth #413 at the 2025 340B Coalition Summer Conference! Listeners are welcome to use code “SpendMend25” to receive a 25% discount for new subscriptions to 340B Report. Visit https://340breport.com/
Health systems eligible for 340B savings must strike a balance by staying compliant with purchasing rules while also maximizing the amount of eligible savings they can obtain to invest in patient care. Angela Campitelli, the director of the pharmacy 340B program at MetroHealth System in Cleveland, explains how a hospital system such as hers implements a purchasing strategy that achieves that balance.Following rules for 340B purchasesDisproportionate share (DSH) hospitals, children's hospitals, and cancer hospitals are subject to a group purchasing organization (GPO) prohibition that bars them from buying covered outpatient drugs on GPO accounts. That requires maintaining a purchasing system that involves buying drugs at wholesale acquisition cost (WAC) for neutral inventory and then replenishing at 340B, WAC, or GPO pricing depending on how the drug is used.How the cycle can break downPurchasing drugs outside of the outlined processes could cause violations of the GPO prohibition or other 340B rules, which could lead to sanctions that might include losing eligibility for 340B. That is why health systems such as MetroHealth use staff education, regular auditing, and other safeguards to ensure they are purchasing and replenishing drugs on the correct accounts.Investments in the strategyCampitelli recommends 340B hospital teams bring their senior leadership on board to invest in auditing and other resources to ensure a strong purchasing strategy. Such investments will help avoid potential rule violations while ensuring that hospitals are not walking away from 340B savings to which they are entitled.Resources340B Health Appeals Rebate Ruling; Federal Court Agrees to Fast-Track Drugmaker Appeals
This podcast will provide members with an update on federal and state action on the 340B program. We'll talk through 340B policy shifts at the federal level and what's happening in the states. We'll also discuss what we're watching as 340B cases make their way through the courts. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Heather and Matthew welcome Chuck Melendi, a seasoned healthcare consultant and former executive with decades of experience in pharmaceuticals, biotech, and medical devices. Chuck joins us to examine the complexities of the federal 340B pricing program, which provides discounted outpatient drugs to eligible health care providers. From ongoing litigation and proposed legislative reform to the role of PBMs, Chuck shares insights into why a seemingly good faith regulation is one of the most debated topics in health care policy. Tune in for a thoughtful discussion on how healthcare leaders and government can preserve the mission of 340B while addressing its challenges.
In this episode, Greg and Rob catch up on developments in the 340B space. They chat about new information provided by CMS for pharmacies related to the Medicare Drug Price Negotiation Program (some helpful links are below). Also, they debate about what might be coming with the widely anticipated 340B rebate model guidance. CMS Medicare Transaction Facilitator (MTF) User Guide: https://www.cms.gov/files/document/negotiation-program-mtf-user-guide.pdf CMS MTF Pharmacy FAQs: https://340breport.com/wp-content/uploads/2025/06/pharmacy-and-dispensing-entity-mtf-faq.pdf
After months of litigation in a federal district court, a key decision recently came out in the legal fight over 340B drug rebates. 340B Health Vice President of Legal and Policy Amanda Nagrotsky updates us on the development.Court deals a blow to drugmakersD.C. district court judge Dabney Friedrich ruled on May 15 that manufacturers cannot unilaterally implement rebate models for 340B, agreeing with the Health Resources & Services Administration (HRSA) that the agency effectively has preapproval authority over rebates. In her decision, the judge cited early results from a 340B Health survey finding that shifting 340B to a rebate model would divert significant hospital resources from patient care. Drugmakers have already appealed the ruling.Some bright spots for drugmakers in this decisionAlthough the decision largely went against pharmaceutical companies, the judge ruled that the 340B statute does not categorically prohibit rebates, leaving the door open for government approvals of rebates. The judge also agreed with drugmakers' assertions that HRSA should consider how rebate models could improve 340B compliance and how requiring the sharing of data through rebates could aid in drug company audits of covered entities.Will HRSA stop all rebates from proceeding?Despite this decision, the legal fight over rebates isn't over yet. The judge found that, for three of the manufacturers in these cases, HRSA has yet to issue final decisions with respect to their proposed rebate models. In the case of Sanofi, the judge found that HRSA failed to adequately explain the legal basis for rejecting the drugmaker's rebate model, and she directed the agency to reconsider its decision and explain whether and how it would violate the 340B statute. HRSA sent rebate guidance to the White House for approval earlier this month, though as of recording this episode it was not known what that guidance would say.ResourcesRead Our Analysis of the First Federal Court Decision on Rebates340B Health Continues Court Fight Against Rebates
In this episode, Garrick J. Stoldt, CFO of Saint Peter's Healthcare System, shares how his team is tackling major challenges including Medicaid cuts, 340B pressures, and rising denials—while staying strategic about AI investments and future-proofing the system. With over 20 years at the helm, he reflects on the evolving role of the CFO and why proactive leadership is more essential than ever.
This week's episode is a quick one. We pushed out this episode expecting to have HRSA guidance on rebate models to discuss, but we'll have to wait for that topic another day! Greg and Rob catch up on a few developments in the 340B news cycle, primarily recapping HRSA's first final agency action taken in the context of 340B ADR claims.
More than a third of patients released from the hospital never fill their discharge prescriptions, but “meds-to-beds” programs can help improve that statistic. That is the approach Renown Health in Reno, Nev., took with the help of its 340B savings. Renown Vice President of Pharmacy Services Adam Porath joins us to describe how this meds-to-beds program improves patient care.Hospital readmissions down, patient convenience upRenown Health's 340B-funded program offers medication to patients who are being discharged from the hospital, either through bedside delivery, pneumatic tube, or a unique discharge lounge. The effort began as a pilot for Medicaid patients in 2016, and it demonstrated patients in the program were 25% less likely to be readmitted to the hospital once discharged. These health improvements plus the added convenience of medication access for patients convinced the system to expand the program.340B pricing to patients who cannot payPorath says Renown Health refers patients who cannot afford discharge medications to its social services team, which can authorize providing the drugs to those patients at the 340B-discounted rate. The team also will work with patients to see if they qualify for coverage such as Medicaid or other programs to reduce their out-of-pocket costs. Porath said Renown's meds-to-beds program provides drugs free of charge to about 30 patients per month.The keys to successRenown Health's meds-to-beds program has been a success, with more than 80% of eligible patients participating as of the end of 2024. The hospital expanded the services to all patients and started operating it 24/7 in April 2024. Porath said the keys to success include regular reporting to stakeholders and innovations to handle a large volume of patients discharging at once. Such changes allow all parties to stay in the loop with the development of the program and to celebrate successes as they occur.ResourcesRead Our Analysis of the First Federal Court Decision on RebatesSecond Federal Judge Allows 340B Health, Member Hospitals To Intervene in Rebate Lawsuit
Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: Alan Condon, “CMS cracks down on states using Medicaid to treat undocumented immigrants,” May 27, 2025, https://www.beckershospitalreview.com/finance/cms-cracks-down-on-states-using-medicaid-to-treat-undocumented-immigrants/, Becker's Hospital Review. KFF Health News, “Health Provisions in the 2025 Federal Budget Reconciliation Bill,” Updated May 22, 2025, https://www.kff.org/tracking-the-medicare-provisions-in-the-2025-budget-bill/. Donna Levally, “Four Changes to Medicare in the One Big Beautiful Bill Act,” Updated May 27, 2025, https://www.kiplinger.com/retirement/medicare/changes-to-medicare-in-the-one-big-beautiful-bill-act, Kiplinger. Chartis, “New Chartis Study Explores Rural Hospital Instability and Models Potential Impact of Rural Emergency Hospital Designation,” February 7, 2023, https://www.chartis.com/about/news/new-chartis-study-explores-rural-hospital-instability-and-models-potential-impact-rural. Madeline Ashely, et. al, “House GOP's 1,112-page budget: 23 notes for hospital leaders,” May 27, 2025, https://www.beckershospitalreview.com/uncategorized/house-gops-1112-page-budget-23-notes-for-hospital-leaders/, Becker's Hospital Review. Noam N. Levey, “In Arizona County That Backed Trump, Conflicted Feelings About Cutting Medicaid,” May 28, 2025, https://kffhealthnews.org/news/article/medicaid-cuts-arizona-county-trump-voters-conflicted/, KFF Health News. Modern Medicaid Alliance, “Opposition Continues to Grow As Proposed Medicaid Cuts Move Forward Through Reconciliation Process,” May 20, 2025, https://modernmedicaid.org/opposition-continues-to-grow-as-proposed-medicaid-cuts-move-forward-through-reconciliation-process/. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com. Follow Rural Health Today on social media! https://x.com/RuralHealthPodhttps://www.youtube.com/@ruralhealthtoday7665 Follow Hillsdale Hospital on social media! https://www.facebook.com/hillsdalehospital/ https://www.twitter.com/hillsdalehosp/ https://www.linkedin.com/company/hillsdale-community-health-center/ https://www.instagram.com/hillsdalehospital/
Dr. Lisa Mathew interviews Dr. Brittany Panico, a rheumatologist in Colorado Springs who recently wrote an op-ed calling for reforms to the 340B program to require more transparency and reporting on how 340B discounts are passed on to patients. The 340B Program is a federal drug pricing program that allows certain hospitals and clinics to buy medications at steep discounts to support medication access for underserved patients, with the expectation that these savings would be passed on to patients. But critics argue that the program's growth has led to unintended consequences, such as market consolidation. And some studies suggest that 340B discounts may not translate into increased care or lower costs for vulnerable populations. Join Dr. Mathew and Dr. Panico as they discuss Dr. Panico's experience as an employed physician in a 340B hospital system and as an independent physician, and how the lack of oversight in the program may be making it harder for specialists to deliver the best patient care. Produced by Andrew Sousa and Hayden Margolis for Steadfast Collaborative, LLC Mixed and mastered by Hayden Margolis Gastro Broadcast, Episode 77, presented by TissueCypher from Castle Biosciences
In this episode, Greg and Rob are joined by guest Peggy Tighe, healthcare attorney and government relations specialist. They catch up on lots of contemporary issues impacting 340B providers, including state legislative activity (19:44), the recent Trump Administration's executive order on drug pricing (30:02), Senator Cassidy's 340B investigation report (43:20), and movement in 340B rebate litigation (52:00). Also, listen for Dave Chappelle and magic mushroom references – this one was a lively discussion! Register for our upcoming Trulla Webinar: https://attendee.gotowebinar.com/register/7502684065481252181?source=340B+Unscripted Attending the 340B Grantees Spring Conference in Kansas City May 27 - 30? Come say hello to our team – we'll be at Booth #24 sharing our insights from our work with the 340B grantee community!
Big potential changes to how 340B operates plus heightened interest in both new protections and new restrictions for covered entities means there is much to keep track of in the 340B world. 340B Health CEO Maureen Testoni joins us to make sense of recent developments in the nation's courts and beyond.Rebates Get Their Day in Court340B Health, two member hospitals, and the government met drug companies in court in late April to challenge drugmaker attempts to replace 340B discounts with rebates. Testoni says the judge cited potentially devastating consequences to hospitals if rebates proceeded but also had probing questions for the government on how it is working to address drugmaker compliance concerns. The Dept. of Health and Human Services is set to release guidance by early June on the rebate issue, and the court's decision could come out soon.The White House Proposes 340B Big Oversight Shift A leaked copy of the Trump administration's latest budget proposal includes a plan to move the Office of Pharmacy Affairs (OPA) from the Health Resources & Services Administration to the Centers for Medicare & Medicaid Services. Testoni says the oversight shift is concerning because of a stark difference between the purpose of 340B and the operations of Medicare and Medicaid. CMS also imposed years of Medicare payment cuts to 340B hospitals that the U.S. Supreme Court eventually overturned.340B Protections, Mandates Take Center StageStates continue enacting laws to protect hospital access to 340B pricing, but they also are moving forward with reporting mandates and proposals to define how hospitals should use their savings. Testoni said reporting and use-of-savings mandates lead to misdirected views on the purpose of 340B, which goes far beyond direct patient care and cost assistance. On Capitol Hill, a report from a long-running investigation of 340B recently came out, contributing to the debate over possible new restrictions.ResourcesFederal Government Signals Upcoming Guidance on 340B Rebate Models Amid Legal ChallengesBrief Your Leaders on White House Plans for Major 340B ChangesNebraska Is 12th State To Enact Contract Pharmacy ProtectionsIndiana Becomes Fifth State To Mandate 340B Reports From HospitalsKey Senator Concludes 340B Investigation, Calls for Major ReformsNew 340B Health Research340B Impact Profiles
Once again, the venerable 340B Drug Pricing Program finds itself in the crosshairs of critics – this time, from the U.S. Congress.Recently, Sen. Bill Cassidy (R-La.), ranking member of the Senate Health, Education, Labor, and Pensions (HELP) Committee, released a report outlining his office's investigation into the program.During the next live edition of Monitor Mondays, 340B Health CEO Maureen Testoni will return to the broadcast to offer her response to the senator's investigation.The long-running broadcast will also include these instantly recognizable features:• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, will be making his Monday Rounds.• The RAC Report: Healthcare attorney Knicole Emanuel, partner at the law firm of Nelson Mullins, will report the latest news about auditors.• Risky Business: Healthcare attorney David Glaser, shareholder in the law offices of Fredrikson & Byron, will join the broadcast with his trademark segment.• Legislative Update: Cate Brantley, senior healthcare government affairs analyst for Zelis, will report on the news at the intersection of healthcare and congressional action.
The federal drug purchasing program known as 340B was created in 1992 to help select provider organizations stretch scarce resources to care for patients. More than three decades later, health systems of all shapes and sizes have come to rely on 340B for their financial sustainability. But the program has come under criticism. And in recent years, it's been under more scrutiny, with manufacturers, state governments, and federal regulators proposing changes to how it operates. In this episode, host Abby Burns invites Advisory Board experts Gina Lohr and Chloe Bakst to unpack the origin and controversy around 340B. They debate whether 340B has strayed from its intended purpose and break down the proposed changes to the program, how likely they are to go into effect, and what those changes would mean for health systems. Plus, stay tuned to the end of the episode, where co-host Rae Woods discusses the recent healthcare-focused executive order and what it signals for the future of this administration's drug policy. Let us know what you think about today's discussion, or share your ideas for future episode topics by leaving us a voice message or emailing us. Links: 340B Drug Pricing Program 340B reimbursement cuts may be looming: What you need to know J&J's 340B rebate model is receiving pushback. Here's why. Congress is weighing spending cuts. How will they impact healthcare? [Relentless Health Value] EP448 (Part 1): 340B: Where It Started, Where It Is Now, and Who Is Really Benefiting From This Massive Program, With Shawn Gremminger [Relentless Health Value] EP448 (Part 2): 340B: Why Employers Should Probably Care About What's Happening Here, With Shawn Gremminger GLP-1 innovation showcase A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.
The federal drug purchasing program known as 340B was created in 1992 to help select provider organizations stretch scarce resources to care for patients. More than three decades later, health systems of all shapes and sizes have come to rely on 340B for their financial sustainability. But the program has come under criticism. And in recent years, it's been under more scrutiny, with manufacturers, state governments, and federal regulators proposing changes to how it operates. In this episode, host Abby Burns invites Advisory Board experts Gina Lohr and Chloe Bakst to unpack the origin and controversy around 340B. They debate whether 340B has strayed from its intended purpose and break down the proposed changes to the program, how likely they are to go into effect, and what those changes would mean for health systems. Plus, stay tuned to the end of the episode, where co-host Rae Woods discusses the recent healthcare-focused executive order and what it signals for the future of this administration's drug policy. Let us know what you think about today's discussion, or share your ideas for future episode topics by leaving us a voice message or emailing us. Links: 340B Drug Pricing Program 340B reimbursement cuts may be looming: What you need to know J&J's 340B rebate model is receiving pushback. Here's why. Congress is weighing spending cuts. How will they impact healthcare? [Relentless Health Value] EP448 (Part 1): 340B: Where It Started, Where It Is Now, and Who Is Really Benefiting From This Massive Program, With Shawn Gremminger [Relentless Health Value] EP448 (Part 2): 340B: Why Employers Should Probably Care About What's Happening Here, With Shawn Gremminger GLP-1 innovation showcase A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.
The 340B program has been active for over 30 years and is dynamic and evolving. Dr. Greg Medley, Senior Director, 340B Drug Pricing Program Services at Vizient joins host Carolyn Liptak, Pharmacy Executive Director with the Vizient Center for Pharmacy Practice Excellence to discuss the impact of the most recent executive order on the 340b program. Guest speakers: Greg Medley, PharmD Senior Director, 340B Drug Pricing Program Services Vizient Inc. Host: Carolyn Liptak, MBA, , BS Pharm Pharmacy Executive Director, Center for Pharmacy Practice Excellence Vizient Inc. Show Notes: [00:53-01:26] Dr. Medley background information [01:27-03:17] What is outlined in the executive order [03:18-05:27] Basics of how 340B works and why its under fire [05:28-09:36] How this new executive order pertains to the 340B program [09:37-13:01] What is learned from the comments on these changes [13:02-14:07] Where can listeners go now to get more information? Links | Resources: JAMA article Click Here Fact Sheet: President Donald J. Trump Announces Actions to Lower Prescription Drug Prices Click Here Lowering Drug Prices by Once Again Putting Americans First Click Here Subscribe Today! Apple Podcasts Amazon Podcasts Spotify Android RSS Feed
The Senate HELP committee report calls for reforms within the 340B drug discount program. Blue Shield of California leaked health data of nearly 5-million members to Google. And, measles misinformation is on the rise nationwide, according to a new poll. That's coming up on today's episode of Gist Healthcare Daily. Hosted on Acast. See acast.com/privacy for more information.
The ancillary outpatient sites known as 340B child sites serve as important places for patients to access the drugs and care they need. There are crucial steps involved in effectively onboarding potential child sites as well as ongoing processes involved with maintaining the parent hospital's partnership with those sites. University Hospitals Cleveland Medical Center 340B Pharmacy Manager Joe Moss joins us to shed light on this process and the potential problems to be on the lookout for.How is a 340B child site onboarded?Moss says the first big step to identifying potential sites is to work with a hospital's finance, revenue, pharmacy, and legal departments to evaluate a site. The team looks at Medicare cost reports and trial balances to ensure they are eligible for 340B. As part of the process, they also use electronic medical record and retail data to identify potential clinic areas based on their patient volumes.A 340B child site is registered. Now what?The work is not over once a child site has been registered in 340B. UH has a program it calls the “340B Concierge Program,” which aims to provide comprehensive, ongoing support and guidance to a given child site. The program offers additional education and information in such areas as procurement processes, the appropriate ways to handle drug transfers, and miscellaneous licensing issues.Onboarding requires relationships and a close eye on complianceMoss says that hospitals onboarding a child site should establish and maintain close ties with the site to prevent issues with 340B compliance. This can involve being the first line for any pharmacy issues the site staff might be having, holding frank conversations with clinic management when necessary, and inviting staff to observe mock audits so they can learn more about what goes into maintaining 340B compliance.Resources:Trump Executive Order Could Revive Medicare 340B Cuts
Send us a textSchedule an Rx AssessmentCracking the 340B code can feel like climbing Mt. Everest…but done right, it can be an absolute game-changer for independent pharmacies. That's what this week's episode of The Bottom Line Pharmacy Podcast is all about! Scotty Sykes, CPA, CFP® and Kathy Blanchard team up with Draven Tell, Lead Analyst at Secure340B to break down: - Low Hanging Fruits With 340B Programs - Why Accumulators Matter and Their Impact on Your Bottom Line - How state legislation is pushing back against manufacturer restrictions Join the discussion with us!Click here for the transcript. Stay connected with Draven Tell and Secure340B: Draven Tell LinkedInSecure 340B WebsiteSecure 340B FacebookSecure 340B Twitter (X)Secure 340B LinkedInSecure340B InstagramStay connected with us: FacebookTwitter (X)LinkedIn InstagramScotty Sykes – CPA, CFP LinkedIn Scotty Sykes – CPA, CFP Twitter More resources on this topic: Podcast | Overcoming Challenges with 340B ContractsPodcast | Understanding 340B Contracts and Maximizing Your Pharmacy's BenefitsClip | The Impact of DIR Fees on 340B Pharmacies
In this episode of the Pharmacy Innovators Podcast, host Jim Jorgenson is joined by two powerhouse voices in the 340B space: Kristin Fox Smith, Visante's own 340B expert, and Ted Slafsky, Publisher & CEO of the 340B Report. Together, they dive into the latest political and regulatory shifts shaking the 340B landscape — from new Congressional leadership and pending legislation to the major reorganization of HHS and HRSA. The episode also explores Medicaid trends, judicial developments, contract pharmacy access, and the broader political forces shaping healthcare access for vulnerable populations. Whether you're a healthcare leader, policymaker, or 340B stakeholder, this episode offers timely and valuable insights into the evolving landscape of the program. 340B Report website: https://340breport.com/ Subscribe now using coupon code VISANTE25
In this episode of Product in Healthtech, we reconnect with Scott Martin, founder and CEO of Rescription, to discover how his company has evolved since our previous conversation.Topics covered:Rescription's "radical clarity" approach to transforming prescription drug costsHow Rescription leverages the 340B federal program as intended to benefit both health systems and patientsResults from partnerships with Bergen New Bridge and Baton Rouge General, showing 27-35% savingsWhy patients under Rescription's model receive zero-dollar copays for prescriptionsThe patent-pending adjudication technology developed with Vynyl that enables upfront processing at scaleRescription's ambitious expansion plans across 14 states and 15 additional health systemsKey moments:[01:16] Scott explains how Rescription's model differs from traditional PBMs[03:09] Clarifying misconceptions about the 340B program[05:14] Updates on partnerships with Bergen New Bridge and Baton Rouge General[07:25] How Rescription addresses pharmaceutical manufacturer pushback[09:24] Details on Rescription's patent-pending adjudication technology[11:15] Future expansion plans and new service offeringsResources mentioned:Wall Street Journal article featuring Rescription (link to be added)Follow Product in Healthtech:Website: productinhealthtech.comLinkedIn: Product in HealthtechEmail: info@productinhealthtech.com Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to sign up for our free webinars, visit www.productinhealthtech.com.
In this week's episode, Greg and Rob are joined by colleague Heidi Larson to recap lots of questions that came out of a recent SpendMend webinar focused on 340B location issues. They'll address issues like what is considered onsite vs. offsite for the purposes of OPAIS registration, when newly registered locations are eligible to use 340B and a variety of other issues pertaining to how entities need to address their locations from a 340B compliance perspective. In the intro, the guys catch up on 340B hot topics in the news. They'll hit highlights of lots of state level activity, discuss ongoing changes in D.C. with federal agency changes, and a new White House executive order with some 340B implications. If you missed the webinar, you can catch it again on demand here: https://ww2.spendmend.com/webinar-all-about-locations-understanding-the-importance-of-location-considerations-in-340b-program-compliance/ If you have any question or topics to suggest, email us at 340BUnscripted@spendmend.com
In this episode, Alan Condon, Editor-in-Chief at Becker's Healthcare, dives into the latest federal policy shifts impacting the 340B drug pricing program and highlights a major acquisition move by Ascension Health.
This podcast will provide members with an analysis of the Trump Administration's Executive Order (EO) on drug pricing. We'll talk through what the EO means for the 340B program, the Inflation Reduction Act's negotiated drug pricing program, and site neutral payment, and what ASHP will be watching in the coming weeks. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Joe Grogan sits down with Dr. Anthony DiGiorgio, a neurosurgeon and health policy researcher, for a wide-ranging conversation on the challenges facing America's healthcare system. Drawing on his experience at a safety net hospital, Dr. DiGiorgio discusses the realities of trauma care, including the treatment of traumatic brain and spinal cord injuries, and the systemic issues within Medicaid that hinder access and quality of care. The conversation also explores the misuse of the 340B program, the ethics and logistics of overlapping surgeries, and the growing crisis of physician burnout. Dr. DiGiorgio shares his advocacy for direct primary care and the promise of AI as tools to reduce administrative burdens and improve patient outcomes.
Health care executive Gavin Magaha discusses his article "Advancing drug discount programs starts with collaboration and clarity." He outlines how the 340B drug discount program, established over 30 years ago, has not evolved with modern health care delivery, leading to complexity, poorly defined standards, compliance issues, and misaligned incentives that hinder its original intent to serve vulnerable patients. Gavin highlights challenges like the outdated package-based discount model, the use of unapproved replenishment methods, and a lack of data transparency contributing to disproportionate program growth—a 23 percent increase in 340B sales versus an 11.4 percent rise in total U.S. drug spending in 2023. The solution, he argues, lies in stakeholder collaboration unified by advanced technology: centralizing data, leveraging analytics and machine learning for transparency and compliance, and creating a single source of truth to foster trust, reduce costs, and ensure the program effectively supports patients. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended
Charlton Park, CFO and Chief Analytics Officer at University of Utah Health, explores the trends the organization is focused on, including AI and automation efforts like AI scribe solutions and streamlining business processes. He also addresses ongoing challenges with payers and the complexities of the 340B drug pricing program. Park outlines how Utah Health is tackling the growing demand for services through a comprehensive growth plan, including the launch of the ambitious "West Valley City Project."
Health Resources & Services Administration (HRSA) audits of hospitals play a key role in ensuring compliance with 340B rules and regulations. In this episode, Dave Lacknauth, executive director of pharmacy services at Broward Health in Fort. Lauderdale, Fla., joins us to discuss the importance of taking a proactive, comprehensive approach to audit readiness with the goal of ensuring clean audit results. Compliance protects 340B accessBeing prepared for HRSA audits serves a crucial function that ultimately benefits the patients whom hospitals serve, Lacknauth explains. Maintaining the integrity of 340B means protecting access to 340B savings that hospitals can invest in crucial care for community members that need it. Continuous audit readinessLacknauth discusses how Broward Health maintains audit readiness by conducting internal audits, bringing in external consultants, and identifying areas of opportunity for improvement. A robust system of internal reviews means that when HRSA comes knocking, Broward Health is already prepared. This was evident after a recent audit of one of the system's hospitals that resulted in zero recommendations for improvement.Organization, resources, transparency are keyPreparing for audits requires a health system to invest time and resources, but Lacknauth stresses that these investments pay off. Engaging a comprehensive team from various departments in the audit readiness process allows for a health system to have the appropriate level of responsiveness and transparency during a HRSA audit.Resources:Nebraska Is 12th State To Enact Contract Pharmacy ProtectionsIdaho Becomes Fourth State To Mandate 340B Reports From Hospitals
On this edition of Inside the 1581, we'll be discussing the 340B drug discount program and its essential role in strengthening the healthcare safety net, especially in rural areas. Trent Bourland, CEO of Coal County General Hospital, and Jay Johnson, president and CEO of DRH Health, Duncan, join us to talk about the 340B program, its impact on hospitals and healthcare providers, and how it affects patients, especially those who rely on it for access to the healthcare they need. We also discuss House Bill 2048, the 340B protection bill now moving through the Oklahoma Legislature.www.insidethe1581.com
In this episode, Greg and Rob are joined by Meetali Desai, a pharmacy business leader for a large health system in New England, to discuss thoughts around projecting the impact that IRA-mandated Medicare drug prices will have on 340B covered entities, which will go into effect in January 2026. Meetali shares her approach to quantifying the impact a 340B provider might feel from the intersection between these two federal programs. She'll also offer her insights into other hot topics in the 340B space. In the intro, the guys will discuss updates in the news, including movement in current litigation between HHS and manufacturers attempting to implement 340B rebate models, as well as some concerns regarding cybersecurity risks in the vendor-space. Email us your questions and topics recommendations – 340BUnscripted@spendmend.com